Literature DB >> 3137056

In vitro activity of LY163892 against pathogens isolated from pediatric patients.

W M Wenman1, P C Kibsey, C A Gratton, V E Knight.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3137056     DOI： 10.1007/bf01962360

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  3 in total

1.  In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis.

Authors:  S Alvarez; M Jones; S Holtsclaw-Berk; J Guarderas; S L Berk
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

Review 2.  Antibiotic resistance in Haemophilus influenzae.

Authors:  A L Smith
Journal:  Pediatr Infect Dis       Date:  1983 Sep-Oct

3.  Antibiotic resistance and Haemophilus influenzae.

Authors:  J Philpott-Howard
Journal:  J Antimicrob Chemother       Date:  1984-03       Impact factor: 5.790
  3 in total
  2 in total

Review 1.  Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D McTavish
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

2.  Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia.

Authors:  O Müller; K Wettich
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.